The most-read coverage of the latest updates in acute myeloid leukemia (AML) for 2025 focused on the evolution of targeted ...
In rodents, Amphista linked its BRD9 degrader AMX-883 to a significant improvement in survival and reduction in disease burden compared to Venclexta. Combining AMX-883 with Venclexta and azacitidine ...
NPM1 minimal residual disease (MRD) positivity before allogeneic hematopoietic cell transplantation is linked to higher relapse rates and lower overall survival in patients with acute myeloid leukemia ...
A new generation of targeted treatments and gentler chemotherapy options for older adults with a new diagnosis of acute ...
Errata: Environmental Impact Assessment of Intravenous Versus Subcutaneous Monoclonal Antibodies: A Carbon Footprint Analysis The classification of AML and therapeutic options are now largely driven ...
A small portion of adults in remission from a deadly blood cancer had persisting mutations that were detected, which predicted their risk of death from having the cancer return About 20,000 adults in ...
SAN DIEGO — A polygenic score can link outcomes in Black pediatric patients with acute myeloid leukemia (AML) to genetic traits that arise more frequently in this population, new data reveal. The ...
Compared with white patients, Black patients with acute myeloid leukemia (AML) were on average more than five years younger ...
PALM BAY, Fla.--(BUSINESS WIRE)--AML Superconductivity and Magnetics and Argonne National Laboratory announced today that one of the world’s most sophisticated superconducting magnet systems passed a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback